Physician profile
Bryan Emmerson
NPI 1700033099
$223,009.95
in general payments reported to CMS, 2019-2025
11 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $4,058 · 2021: $204K · 2022: $101 · 2023: $8,780 · 2024: $5,185 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $2,499 · Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,635.00 |
| Travel and Lodging | $2,498.81 |
| Food and Beverage | $709.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $196,228.87 | 2021-2025 | Djo Surgical |
| Orthalign INC | $11,261.34 | 2019-2024 | Orthalign Plus |
| Insight Medical Systems, INC. | $9,404.10 | 2019-2021 | |
| Medical Device Business Services, INC. | $5,135.00 | 2024 | |
| Depuy Synthes Sales INC. | $285.86 | 2020-2021 | |
| Naviswiss, INC. | $241.91 | 2023 | Naviswiss Hip/Knee Navigation |
| Zimmer Biomet Holdings, INC. | $227.89 | 2019-2020 | |
| Heron Therapeutics, INC. | $109.44 | 2023 | Zynrelef |
| Stryker Corporation | $53.93 | 2023 | Gamma, Variax, Augment Injectable |
| Ferring Pharmaceuticals INC. | $39.06 | 2019 | |
| Si-Bone, INC. | $22.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$241,714.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Emmerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.